Trial Results: Social media chatter around BioVie centers on the recent Phase 2 SUNRISE-PD trial data for its Parkinson's treatment, with observers noting the potential for the stock to push past key resistance levels if momentum builds.
Market Watch: Participants highlight unchanged fundamentals amid high short interest and an upcoming S-1 filing, while pointing to upcoming Phase 3 plans and long COVID data as key factors that could influence sentiment in the coming weeks.
Catalyst Focus: The overall tone reflects cautious optimism as investors track volume and follow-through after the clinical update, with some expressing interest in the biotech's next steps without committing to specific price targets.
Note: This discussion summary was generated from an AI condensation of post data.
BioVie Insider Trading Activity
BioVie insiders have traded $BIVI stock on the open market 4 times in the past 6 months. Of those trades, 4 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $BIVI stock by insiders over the last 6 months:
- CUONG V DO (President & CEO) purchased 15,210 shares for an estimated $31,636
- JOSEPH M PALUMBO (Chief Medical Officer) purchased 4,843 shares for an estimated $10,460
- JOANNE WENDY KIM (Chief Financial Officer) purchased 2,500 shares for an estimated $5,450
- AMY SUZON CHAPPELL purchased 727 shares for an estimated $1,570
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
BioVie Hedge Fund Activity
We have seen 15 institutional investors add shares of BioVie stock to their portfolio, and 19 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MORGAN STANLEY added 530,250 shares (+704.9%) to their portfolio in Q2 2026, for an estimated $1,028,685
- DRW SECURITIES, LLC removed 128,356 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $179,698
- DIAMETRIC CAPITAL, LP removed 113,364 shares (-30.6%) from their portfolio in Q2 2026, for an estimated $219,926
- RENAISSANCE TECHNOLOGIES LLC added 60,000 shares (+88.3%) to their portfolio in Q2 2026, for an estimated $116,400
- PRELUDE CAPITAL MANAGEMENT, LLC removed 59,480 shares (-64.6%) from their portfolio in Q2 2026, for an estimated $115,391
- CITADEL ADVISORS LLC added 50,660 shares (+111.9%) to their portfolio in Q2 2026, for an estimated $98,280
- PHILADELPHIA TRUST CO removed 25,000 shares (-33.3%) from their portfolio in Q2 2026, for an estimated $48,500
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
